BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208.9 USD | +3.18% |
|
+7.47% | -19.27% |
| 26/04 | Guggenheim Adjusts Price Target on Biogen to $255 From $275 | MT |
| 25/04 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOGEN INC. | Biopharmaceuticals | +3.18% | +7.47% | -19.27% | -27.48% | -9.38% | 30.42B |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- BIIB Stock
- Charts Biogen Inc.
- Comparison Chart
